Patents by Inventor Sara BELLI

Sara BELLI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMES FOR TREATMENT OF SYNUCLEINOPATHIES
    Publication number: 20210079103
    Abstract: The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.
    Type: Application
    Filed: July 23, 2020
    Publication date: March 18, 2021
    Inventors: Jay Soto, Daniel Keith Ness, Martin Koller, Diane Mould, Frank Boess, Meret Martin-Facklam, Valerie Cosson, Hans Peter Grimm, Ronald Gieschke, Sara Belli, Silke Weber
  • DOSING REGIMES FOR TREATMENT OF SYNUCLEINOPATHIES
    Publication number: 20190153102
    Abstract: The invention provides dosage regimes for treatment of synucleinopathies. In one regime, a subject receives 3000-5000 mg of an antibody intravenously every 3-5 weeks. In another regime, a subject receives 1300-1700 mg of an antibody intravenously every 3-5 weeks.
    Type: Application
    Filed: September 28, 2018
    Publication date: May 23, 2019
    Inventors: Jay Soto, Daniel Keith Ness, Martin Koller, Diane Mould, Frank Boess, Meret Martin-Fracklam, Valerie Cosson, Hans Peter Grimm, Ronald Gieschke, Sara Belli, Silke Weber
  • Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
    Patent number: 10137170
    Abstract: Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 27, 2018
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, HOFFMANN-LA ROCHE INC.
    Inventors: Sara Belli, Konrad Bleicher, Richard D. Dimarchi, Eike Hoffmann, Eric A. Kitas, Anish A. Konkar
  • LIPIDATED INCRETIN RECEPTOR LIGAND HUMAN IMMUNOGLOBULIN FC-REGION FUSION POLYPEPTIDES
    Publication number: 20160310575
    Abstract: Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 27, 2016
    Inventors: Sara BELLI, Konrad BLEICHER, Richard D. DIMARCHI, Eike HOFFMANN, Eric A. KITAS, Anish A. KONKAR